Galderma Holding S.A.
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Nestlé Skin Health S.A. (to 2020)
10
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 28 to 30, 2026 · next Nov 28
- 1 fee due Dec 25, 2026The maintenance fee for Compound from the avermectin family for treating and/or preventing folliculitis (US 10,328,094) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 3 fees due Jan 18 to 28, 2027 · next Jan 18
- 2 fees due Feb 13 to 22, 2027 · next Feb 13
- 1 fee due Mar 3, 2027The maintenance fee for Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis (US 10,398,720) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for Carbohydrate Crosslinker (US 11,780,970) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 4 fees due Jul 9 to 12, 2027 · next Jul 9
- 3 fees due Aug 11 to 13, 2027 · next Aug 11
- 1 fee due Sep 26, 2027The maintenance fee for Method for Preparing Acylated Crosslinked Glycosaminoglycans (US 11,939,433) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for BPO wash gel composition (US 10,610,594) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 18, 2026
- 5 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,795,425 | Production of bepromoline In force · From the USPTO record | In force | From the USPTO record | |
| US 8,859,603 | Method for solubilizing metronidazole In force · From the USPTO record | In force | From the USPTO record | |
| US 7,981,916 | Solubilizing of metronidazole In force · From the USPTO record | In force | From the USPTO record | |
| US 7,838,563 | Compounds, formulations, and methods for ameliorating telangiectasias In force · From the USPTO record | In force | From the USPTO record | |
| US 8,858,967 | Dermatological cream-gels containing avermectin compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,778,909 | Method of Applying an Injectable Filler In force · High confidence | In force | High confidence | |
| US 8,049,007 | Preparation of amorolfine In force · From the USPTO record | In force | From the USPTO record | |
| US D727,727 | Sliding overcap for dispensing container In force · From the USPTO record | In force | From the USPTO record | |
| US D734,153 | Closure for a container In force · From the USPTO record | In force | From the USPTO record | |
| US D758,048 | Garment In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 89: 12 patents in force now held by others · 61 lapsed for an unpaid fee · 42 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 9 abandoned · 108 no status recorded